Amneal Pharmaceuticals, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2015 | — | — | $65.1M |
| Dec 2016 | — | — | $27.4M |
| Jun 2017 | — | — | $48.2M |
| Sep 2017 | — | — | $19.3M |
| Oct 2017 | — | $0 | $0 |
| Dec 2017 | $1.36B | $0 | $74.2M |
| Mar 2018 | — | $0 | $48.2M |
| Jun 2018 | $2.64B | $494.5M | $61.5M |
| Sep 2018 | $2.68B | $501.1M | $165.2M |
| Dec 2018 | $2.63B | $504.8M | $213.4M |
| Mar 2019 | $2.63B | $472.2M | $63.9M |
| Jun 2019 | $2.62B | $459.7M | $54.9M |
| Sep 2019 | $2.61B | $218.0M | $212.7M |
| Dec 2019 | $2.61B | $232.0M | $151.2M |
| Mar 2020 | $2.77B | $318.4M | $405.2M |
| Jun 2020 | $2.76B | $306.0M | $266.1M |
| Sep 2020 | $2.76B | $301.0M | $281.3M |
| Dec 2020 | $2.74B | $303.3M | $341.4M |
| Mar 2021 | $2.73B | $323.0M | $452.1M |
| Jun 2021 | $2.72B | $346.1M | $278.3M |
| Sep 2021 | $2.69B | $350.5M | $302.7M |
| Dec 2021 | $2.68B | $360.3M | $247.8M |
| Mar 2022 | $2.67B | $391.1M | $210.5M |
| Jun 2022 | $2.62B | $280.3M | $92.0M |
| Sep 2022 | $2.61B | $297.5M | $87.3M |
| Dec 2022 | $2.59B | $298.4M | $26.0M |
| Mar 2023 | $2.56B | $294.4M | $144.7M |
| Jun 2023 | $2.55B | $318.2M | $109.3M |
| Sep 2023 | $2.54B | $330.9M | $86.9M |
| Dec 2023 | $2.39B | $19.8M | $91.5M |
| Mar 2024 | $2.38B | $-63.7M | $46.5M |
| Jun 2024 | $2.18B | $-57.5M | $43.8M |
| Sep 2024 | $2.17B | $-93.4M | $74.0M |
| Dec 2024 | $2.16B | $-109.3M | $110.6M |
| Mar 2025 | $2.15B | $-131.7M | $59.2M |
| Jun 2025 | $2.15B | $-112.1M | $71.5M |
| Sep 2025 | $2.57B | $-109.5M | $201.2M |
| Dec 2025 | $2.57B | $-70.8M | $282.0M |
| Mar 2026 | $2.57B | $-45.4M | $197.7M |
| Jun 2026 | $2.56B | $33.0M | $127.6M |
| Sep 2026 | $2.92B | $531.3M | $157.4M |